Cognitive ⏱ Half-life: Complex mixture — individual peptide components have varying half-lives. Functional neuroprotective effects persist beyond plasma clearance. Approved Abroad

Cerebrolysin

Cerebrolysin (Brain-Derived Peptide Preparation)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusApproved Abroad
Porcine brain-derived peptide mixture; approved in Russia, China, Austria, S. Korea & 50+ countries for stroke/dementia/TBI. Not FDA-approved.
Human evidenceExtensive
Animal evidenceExtensive

Dozens of randomized human trials exist for stroke, vascular dementia and TBI, but effect sizes are modest, studies are largely manufacturer-funded, and Cochrane reviews found no benefit on death or dependency after ischemic stroke.

What the research does not support

  • It is not FDA-approved and is not an established treatment for stroke, dementia, or TBI in the United States.
  • Cochrane reviews found no benefit on death or dependency after acute ischemic stroke and flagged a rise in serious adverse events.
  • It is not a proven cognitive enhancer for healthy people.
  • Reported dementia benefits are modest and come mostly from manufacturer-funded trials of low-to-very-low certainty.
Half-Life
Complex mixture — individual peptide components have varying half-lives. Functional neuroprotective effects persist beyond plasma clearance.
Mol. Weight
Complex mixture (~10,000 Da average)

What is Cerebrolysin?

Cerebrolysin is the most widely used neuropeptide preparation globally, approved in over 50 countries for neurological conditions. As a complex mixture of brain-derived peptides, it provides multi-target neurotrophic support rather than acting through a single receptor pathway.

Research Applications

Approved clinical indications (non-US) include post-stroke recovery, vascular and Alzheimer’s dementia, traumatic brain injury, and pediatric neurodevelopmental support. Research contexts include neuroplasticity, neuroprotection, and cognitive rehabilitation.

Dosage Information (Research Use)

Clinical protocols: 10-30 mL IV infusion or IM injection daily for 10-20 day courses. Repeated courses at intervals. Requires medical supervision.

Reconstitution & Handling

Supplied as ready-to-use solution. Dilute in 0.9% saline for IV infusion. Do not mix with other medications.

Half-Life & Pharmacokinetics

Complex mixture — individual peptide components have varying half-lives. Functional neuroprotective effects persist beyond plasma clearance.

Reported Observations in Literature

Generally well-tolerated in clinical use. Headache, dizziness, injection site reactions. Rare: agitation, confusion (typically in elderly patients at higher doses).

Key Research References

  • Chen N, et al. “Cerebrolysin for vascular dementia.” Cochrane Database Syst Rev. 2013
  • Muresanu DF, et al. “Cerebrolysin and Recovery After Stroke (CARS).” J Neural Transm. 2016

How Cerebrolysin Works

Cerebrolysin is an enzymatic preparation of porcine brain-derived peptides containing low-molecular-weight neuropeptides and free amino acids. It mimics the action of endogenous neurotrophic factors (BDNF, NGF, CNTF, GDNF) without being a single specific molecule. Mechanism involves neuroplasticity enhancement, anti-apoptotic signaling in neurons, reduction of excitotoxicity (glutamate-mediated damage), and promotion of neurogenesis. The peptide mixture appears to activate multiple complementary neuroprotective pathways simultaneously.

Research Findings

Approved in over 50 countries (not US FDA) for stroke, traumatic brain injury, and dementia. Cochrane review found modest benefits for vascular dementia. Large clinical trial database exists (CASTA for stroke, CERE-COMP for comparison studies). Used extensively in Europe, Asia, and Latin America. Administered IV or IM — not subcutaneous. Requires medical supervision.

Dosage & Administration

Clinical protocols: 10-30 mL IV infusion or IM injection daily for 10-20 day courses. Repeated courses at intervals. Requires medical supervision.

Safety & Side Effects

Generally well-tolerated in clinical use. Headache, dizziness, injection site reactions. Rare: agitation, confusion (typically in elderly patients at higher doses).

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Enzymatic digest of porcine brain proteins — mixture of neuropeptides and free amino acids
Molecular Weight Complex mixture (~10,000 Da average)
Half-Life Complex mixture — individual peptide components have varying half-lives. Functional neuroprotective effects persist beyond plasma clearance.
Available Sizes 10mL vials
Storage Refrigerate 2-8°C. Protect from light. Do not freeze.

Key Research References

  • Chen N, et al. "Cerebrolysin for vascular dementia." Cochrane Database Syst Rev. 2013
  • Muresanu DF, et al. "Cerebrolysin and Recovery After Stroke (CARS)." J Neural Transm. 2016

Related Peptides

View all →
Cortistatin
Cognitive
Neuropeptide with potent anti-inflammatory and immunomodulatory properties, closely related to somatostatin but with distinct therapeutic potential.
View Profile →
Nesfatin-1
Cognitive
An 82-amino acid peptide derived from nucleobindin-2 that regulates appetite, metabolism, and energy homeostasis.
View Profile →
Dihexa
Cognitive
Angiotensin IV analog reported to be 10 million times more potent than BDNF for synaptogenesis in animal models.
View Profile → Buy Now